

# E Magnus Ohman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5386659/e-magnus-ohman-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33  
papers

5,774  
citations

13  
h-index

35  
g-index

35  
ext. papers

6,877  
ext. citations

8.5  
avg, IF

4.17  
L-index

#	Paper	IF	Citations
33	Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 98, E501-E512	2.7	1
32	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , <b>2021</b> , 42, 4683-4693	9.5	5
31	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 162-171	15.1	17
30	Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 1280-1283	3	0
29	Understanding the patient experience of pain and discomfort during cardiac catheterization. <i>Catheterization and Cardiovascular Interventions</i> , <b>2020</b> , 95, E196-E200	2.7	2
28	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2032-2042	59.2	395
27	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 680-684	16.2	7
26	Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. <i>International Journal of Cardiology</i> , <b>2019</b> , 291, 36-41	3.2	2
25	Logistical Challenges Associated With Implementing Precision Medicine-Reply. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 1301	16.2	1
24	Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 430-437	3.8	3
23	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 1322-1329	3	2
22	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet, The</i> , <b>2017</b> , 389, 1799-1808	40	132
21	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 443-454	4.3	31
20	Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TarGeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 231-42	4.3	79
19	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1289-97	15.1	13
18	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 73-9	16.2	13
17	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 936-947	15.1	32

16	Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial. <i>Stroke</i> , <b>2016</b> , 47, 1135-9	6.7	7
15	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. <i>European Heart Journal</i> , <b>2016</b> , 37, 412-22	9.5	15
14	Assessing Quality of Life and Medical Care in Chronic Angina: An Internet Survey. <i>Interactive Journal of Medical Research</i> , <b>2016</b> , 5, e12	2.1	3
13	Philanthropy for Science: Is It a Viable Option?. <i>Circulation Research</i> , <b>2016</b> , 119, 1057-1059	15.7	8
12	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. <i>Heart</i> , <b>2016</b> , 102, 1221-9	5.1	2
11	Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>American Heart Journal</i> , <b>2016</b> , 170, 55-61	4.9	2
10	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , <b>2016</b> , 182, 125-134	4.9	84
9	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 497-506	3.3	4
8	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 329-37	3.3	5
7	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , <b>2015</b> , 170, 683-694 e3	4.9	22
6	Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. <i>Heart</i> , <b>2015</b> , 101, 279-86	5.1	9
5	Impact of nonculprit vessel myocardial perfusion on outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes: analysis from the ACUTY trial (Acute Catheterization and Urgent Intervention Triage Strategy). <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 211-25	5	2
4	Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1638-45	3	6
3	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 1581-98	15.1	2143
2	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. <i>Circulation</i> , <b>2011</b> , 123, 2736-47	16.7	2467
1	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUTY trial. <i>European Heart Journal</i> , <b>2009</b> , 30, 1457-66	9.5	260